Tag: GlobeNewswire

Additional poster presentations highlight Vafseo® (vadadustat) clinical and economic data

WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced upcoming presentations at the American Society of Nephrology Kidney Week 2026 (ASN Kidney Week), which will take place in Denver, CO from October 21-25, 2026. U.S. Renal Care will present the results of the VOICE trial evaluating the safety of three-times-weekly vadadustat compared with an erythropoiesis-stimulating agent (ESA) in patients receiving in-center hemodialysis as a late-breaking presentation. Additionally, Akebia will have multiple poster presentations featuring its rare kidney disease pipeline, including a poster highlighting preclinical research of praliciguat in focal segmental glomerulosclerosis (FSGS), the Phase 2 trial evaluating praliciguat in FSGS, and the Phase 2 basket trial of ebribafusp alfa in complement-mediated kidney diseases. Akebia will also present posters evaluating clinical and economic outcomes associated with Vafseo® (vadadustat).

ASN Kidney Week attendees can visit Akebia at Booth #682 in the Exhibit Hall.

Late-breaking presentation by U.S. Renal Care details:

Vadadustat Three Times Weekly for the Treatment of Anemia in Patients Receiving Hemodialysis
Presenter: Geoffrey A. Block, M.D., FASN, Associate Chief Medical Officer and Senior Vice President, Clinical Research & Medical Affairs for U.S. Renal Care
Date and Time: October 23, 2026; 12:00 to 12:15 PM MT

Akebia-supported posters to be presented in the Exhibit Hall

Posters related to rare kidney disease pipeline:

Renal-Protective Effects of Praliciguat in Preclinical Models of Focal Segmental Glomerulosclerosis
Poster #: TH-PO0380
Date and Time: October 22, 2026; 10:00 AM to 12:00 PM MT

A Phase 2 Trial of Praliciguat Therapy in Patients with FSGS
Poster #: INFO18-SA
Date and Time: October 24, 2026; 10:00 AM to 12:00 PM MT

Tissue-Targeted Complement Inhibition in Rare Kidney Disease: A Phase 2 Open-Label Basket Trial of Ebribafusp Alfa
Poster #: INFO12-SA
Date and Time: October 24, 2026; 10:00 AM to 12:00 PM MT

Posters related to Vafseo® (vadadustat):

Cost Analysis of Hospitalizations for Vadadustat vs. Darbepoetin Alfa Based on the Phase 3 INNO₂VATE Trials
Poster #: FR-PO0609
Date and Time: October 23, 2026; 10:00 AM to 12:00 PM MT

Comparison of Major Adverse Cardiovascular Events with Once-Daily vs. Three-Times-Weekly Vadadustat Dosing in Patients with Dialysis-Dependent CKD
Poster #: SA-PO1096
Date and Time: October 24, 2026; 10:00 AM to 12:00 PM

Comparison Between Vadadustat Exposure (Cmax) and Major Adverse Cardiovascular Events in Patients with Dialysis-Dependent CKD
Poster #: SA-PO1097
Date and Time: October 24, 2026; 10:00 AM to 12:00 PM MT

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Waltham, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

About Vafseo® (vadadustat) tablets
Vafseo® (vadadustat) tablets is a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin, increasing hemoglobin and red blood cell production to manage anemia. Vafseo is approved for use in 37 countries.

INDICATION
VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.

Limitations of Use

• VAFSEO has not been shown to improve quality of life, fatigue, or patient well-being.
• VAFSEO is not indicated for use:
  • As a substitute for red blood cell transfusions in patients who require immediate correction of anemia.
  • In patients with anemia due to CKD not on dialysis.

IMPORTANT SAFETY INFORMATION about VAFSEO (vadadustat) tablets

WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, and THROMBOSIS OF VASCULAR ACCESS.

VAFSEO increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE).

Targeting a hemoglobin level greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events, as occurs with erythropoietin stimulating agents (ESAs), which also increase erythropoietin levels.

No trial has identified a hemoglobin target level, dose of VAFSEO, or dosing strategy that does not increase these risks.

Use the lowest dose of VAFSEO sufficient to reduce the need for red blood cell transfusions.

CONTRAINDICATIONS

• Known hypersensitivity to VAFSEO or any of its components
• Uncontrolled hypertension

WARNINGS AND PRECAUTIONS

• Increased Risk of Death, Myocardial Infarction (MI), Stroke, Venous Thromboembolism, and Thrombosis of Vascular Access
  A rise in hemoglobin (Hb) levels greater than 1 g/dL over 2 weeks can increase these risks. Avoid in patients with a history of MI, cerebrovascular event, or acute coronary syndrome within the 3 months prior to starting VAFSEO. Targeting a Hb level of greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events. Use the lowest effective dose to reduce the need for red blood cell (RBC) transfusions. Adhere to dosing and Hb monitoring recommendations to avoid excessive erythropoiesis.

• Hepatotoxicity
  Hepatocellular injury attributed to VAFSEO was reported in less than 1% of patients, including one severe case with jaundice. Elevated serum ALT, AST, and bilirubin levels were observed in 1.8%, 1.8%, and 0.3% of CKD patients treated with VAFSEO, respectively. Measure ALT, AST, and bilirubin before treatment and monthly for the first 6 months, then as clinically indicated. Discontinue VAFSEO if ALT or AST is persistently elevated or accompanied by elevated bilirubin. Not recommended in patients with cirrhosis or active, acute liver disease.

• Hypertension
  Worsening of hypertension was reported in 14% of VAFSEO and 17% of darbepoetin alfa patients. Serious worsening of hypertension was reported in 2.7% of VAFSEO and 3% of darbepoetin alfa patients. Cases of hypertensive crisis, including hypertensive encephalopathy and seizures, have also been reported in patients receiving VAFSEO. Monitor blood pressure. Adjust anti-hypertensive therapy as needed.

• Seizures
  Seizures occurred in 1.6% of VAFSEO and 1.6% of darbepoetin alfa patients. Monitor for new-onset seizures, premonitory symptoms, or change in seizure frequency.

• Gastrointestinal (GI) Erosion
  Gastric or esophageal erosions occurred in 6.4% of VAFSEO and 5.3% of darbepoetin alfa patients. Serious GI erosions, including GI bleeding and the need for RBC transfusions, were reported in 3.4% of VAFSEO and 3.3% of darbepoetin alfa patients. Consider this risk in patients at increased risk of GI erosion. Advise patients about signs of erosions and GI bleeding and urge them to seek prompt medical care if present.

• Serious Adverse Reactions in Patients with Anemia Due to CKD and Not on Dialysis
  The safety of VAFSEO has not been established for the treatment of anemia due to CKD in adults not on dialysis and its use is not recommended in this setting. In large clinical trials in adults with anemia of CKD who were not on dialysis, an increased risk of mortality, stroke, MI, serious acute kidney injury, serious hepatic injury, and serious GI erosions was observed in patients treated with VAFSEO compared to darbepoetin alfa.

• Malignancy
  VAFSEO has not been studied and is not recommended in patients with active malignancies. Malignancies were observed in 2.2% of VAFSEO and 3.0% of darbepoetin alfa patients. No evidence of increased carcinogenicity was observed in animal studies.

ADVERSE REACTIONS

• The most common adverse reactions (occurring at ≥ 10%) were hypertension and diarrhea.

DRUG INTERACTIONS

• Iron supplements and iron-containing phosphate binders: Administer VAFSEO at least 1 hour before products containing iron.
• Non-iron-containing phosphate binders: Administer VAFSEO at least 1 hour before or 2 hours after non-iron-containing phosphate binders.
• BCRP substrates: Monitor for signs of substrate adverse reactions and consider dose reduction.
• Statins: Monitor for statin-related adverse reactions. Limit the daily dose of simvastatin to 20 mg and rosuvastatin to 5 mg.

USE IN SPECIFIC POPULATIONS

• Pregnancy: May cause fetal harm. A pregnancy exposure registry is available to monitor outcomes in women exposed to VAFSEO during pregnancy. Report pregnancies to 1-844-445-3799.
• Lactation: Breastfeeding not recommended until two days after the final dose.
• Hepatic Impairment: Not recommended in patients with cirrhosis or active, acute liver disease.

Please note that this information is not comprehensive. Please click here for the Full Prescribing Information, including BOXED WARNING and Medication Guide.

Akebia Therapeutics® and Vafseo® are registered trademarks of Akebia Therapeutics, Inc.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

• Secondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression

CONSHOHOCKEN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced the publication of a pre-specified secondary analysis from the Phase 3 MAESTRO-NASH trial in the Journal of Hepatology evaluating whether common genetic risk variants associated with MASH altered patient response to Rezdiffra^® (resmetirom).

The analysis demonstrated that treatment with Rezdiffra resulted in fibrosis improvement, MASH resolution and liver fat and biomarker reductions across patients with several well-established genetic variants associated with MASH progression, including PNPLA3, HSD17B13, TM6SF2, MTARC1 and MBOAT7. The findings suggest that Rezdiffra may have a therapeutic effect regardless of genetic risk factors that contribute to more severe disease.

“Understanding how common MASH risk alleles may influence a patient’s response to treatment will be increasingly important as the treatment landscape and number of diagnosed patients continue to evolve. For example, there is emerging evidence suggesting that response to various therapies could differ in individuals with MASH carrying the PNPLA3 allele, and it will be important to perform similar analyses for other approved and investigational MASH therapies moving forward,” said Naga Chalasani, M.D., David W. Crabb Professor of Gastroenterology and Hepatology at Indiana University School of Medicine and lead author of the study. “It is encouraging to see that Rezdiffra demonstrated consistent effects on liver histology and biomarkers across the genetic risk subgroups evaluated, supporting broad applicability across patients with this serious liver disease.”

“MASH is a complex, heterogeneous disease driven by both metabolic and genetic factors,” said David Soergel, M.D., Chief Medical Officer of Madrigal. “These data reinforce that Rezdiffra provides broad benefit across patients with MASH, including those with the most common genetic risk variants that may put them at higher risk of disease progression, cirrhosis and liver cancer, strengthening its position as a foundation of MASH treatment. These results also support our pipeline strategy of developing precision approaches targeting well-defined genetic drivers of disease that may complement Rezdiffra in specific patient populations.”

About the Analysis
The publication, “Effects of select MASH risk genotypes on resmetirom efficacy on liver histology and biomarkers in patients with MASH and liver fibrosis: a secondary analysis of the MAESTRO-NASH trial,” reports results from a pre-specified secondary analysis of 738 patients from the Phase 3 MAESTRO-NASH trial who consented to genetic testing and completed baseline and Week 52 liver biopsies. The analysis was not prospectively powered to detect small genotype-by-treatment interactions, and only select common variants were assessed. Across all major efficacy endpoints, including MASH resolution, fibrosis improvement, MRI-PDFF reduction and multiple biomarkers, there was no meaningful difference in treatment response based on MASH genetic risk variants or a composite genetic risk score.

Among the findings:

• Resmetirom responses were consistent across PNPLA3, HSD17B13, TM6SF2, MTARC1 and MBOAT7 risk groups for MASH resolution, fibrosis improvement and MRI-PDFF reduction.
• The treatment effect remained consistent after accounting for sex and Hispanic ethnicity.
• Results suggested Rezdiffra’s mechanism of action as a thyroid hormone receptor-beta (THR-β) agonist is not affected by common genetic pathways associated with MASH progression and severity.
• Patients with high-risk genotypes of PNPLA3 or HSD17B13 demonstrated reduced frequency of metabolic risk factors, including diabetes and hypertension, suggesting patients with greater genetic risk could still have high stages of fibrosis, even if they had fewer traditional metabolic risk factors.
• Because this was a secondary analysis with limited numbers in some genotype groups, smaller genotype-specific effects or rarer variants cannot be excluded.
• In the overall MAESTRO-NASH trial (n=966), Rezdiffra was generally well tolerated, with the frequency of serious adverse events similar across treatment groups. See additional risk information below.

Madrigal’s R&D strategy includes developing therapies that target validated disease mechanisms and may complement Rezdiffra’s broad therapeutic effects, especially in patient populations with specific needs. In May 2026, the company announced the addition of MGL-0795 (formerly ARO-PNPLA3), a clinical-stage, small interfering RNA (siRNA) asset targeting PNPLA3 to its pipeline as a potential precision-medicine approach. Mutations in the PNPLA3 gene are strongly associated with MASH progression and a high risk of developing hepatocellular carcinoma (HCC). Madrigal will consult with the FDA on design of a Phase 2 combination trial with Rezdiffra.

In this analysis, MASH resolution in the PNPLA3 subgroup was achieved in 38.4%, 30.8% and 30.5% of Rezdiffra-treated patients, versus 12.9%, 5.1% and 11.7% in patients in the placebo group across low, intermediate and high-risk genotypes, respectively, while fibrosis improvement was 34.2%, 29.5% and 31.4% versus 14.1%, 13.7% and 15.0%, respectively.

About MASH
Metabolic dysfunction-associated steatohepatitis (MASH) is a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, the need for liver transplantation and premature mortality. MASH is the leading cause of liver transplantation in women and the second leading cause of all liver transplantation in the U.S., and the fastest-growing indication for liver transplantation in Europe.

Once patients progress to MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), the risk of adverse liver outcomes increases dramatically: these patients have a 10 to 17 times higher risk of liver-related mortality as compared to patients without fibrosis.

Patients with MASH who progress to cirrhosis face a 42 times higher risk of liver-related mortality, underscoring the need to treat MASH before complications of cirrhosis develop. MASH is also an independent driver of cardiovascular disease, the leading cause of mortality for patients.

As disease awareness improves and disease prevalence increases, the number of patients diagnosed with F2 to F4c MASH is growing.

About Rezdiffra
What is Rezdiffra?
Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.

This indication is approved based on improvement of MASH and liver scarring (fibrosis). There are ongoing studies to confirm the clinical benefit of Rezdiffra.

Before you take Rezdiffra, tell your healthcare provider about all of your medical conditions, including if you:

• have any liver problems other than MASH.
• have gallbladder problems or have been told you have gallbladder problems, including gallstones.
• are pregnant or plan to become pregnant. It is not known if Rezdiffra will harm your unborn baby.
  • A pregnancy safety study for women who take Rezdiffra during pregnancy collects information about the health of you and your baby. You or your healthcare provider can report your pregnancy by visiting https://pregnancyregistry.madrigalpharma.com/ or calling 1-800-905-0324.
• are breastfeeding or plan to breastfeed. It is not known if Rezdiffra passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take Rezdiffra.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

• Rezdiffra and other medicines may affect each other, causing side effects. Rezdiffra may affect the way other medicines work, and other medicines may affect how Rezdiffra works.
• Especially tell your healthcare provider if you take medicines that contain gemfibrozil to help lower your triglycerides, because Rezdiffra is not recommended in patients taking these medicines.
• Tell your healthcare provider if you are taking medicines such as clopidogrel to thin your blood or statin medicines to help lower your cholesterol.
• Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

What are the possible side effects of Rezdiffra?
Rezdiffra may cause serious side effects, including:

• liver injury (hepatotoxicity). Stop taking Rezdiffra and call your healthcare provider right away if you develop the following signs or symptoms of hepatotoxicity: tiredness, nausea, vomiting, fever, rash, your skin or the white part of your eyes turns yellow (jaundice) or stomach pain/tenderness.
• gallbladder problems. Gallbladder problems such as gallstones, or inflammation of the gallbladder, or inflammation of the pancreas from gallstones can occur with MASH and may occur if you take Rezdiffra. Call your healthcare provider right away if you develop any signs or symptoms of these conditions including nausea, vomiting, fever, or pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen to your back and the pain may happen with or without vomiting.
• The most common side effects of Rezdiffra include: diarrhea, nausea, itching, stomach pain, vomiting, dizziness and constipation.

These are not all the possible side effects of Rezdiffra. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Madrigal at 1-800-905-0324.

Please see the full Prescribing Information, including Patient Information, for Rezdiffra.

About Madrigal
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com and follow us on LinkedIn.

Forward-Looking Statements
This press release includes “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements related to the therapeutic effect of Rezdiffra across genetic variants associated with MASH, Madrigal’s ability to develop its pipeline and the potential benefit of Madrigal’s pipeline candidates for the treatment of MASH. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to: the assumptions underlying the forward-looking statements; our ability to successfully commercialize Rezdiffra in the U.S. and Europe; risks related to obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or rejections; our history of operating losses and the possibility that we may never achieve or maintain profitability; risks associated with meeting the objectives of our clinical trials, including, but not limited to our ability to achieve enrollment objectives concerning patient numbers (including an adequate safety database), outcomes objectives and/or timing objectives for our trials; any delays or failures in enrollment, and the occurrence of adverse safety events; risks related to the effects of Rezdiffra’s (resmetirom’s) mechanism of action or of any other product candidate; market demand for and acceptance of Rezdiffra; our ability to service indebtedness and otherwise comply with debt covenants; outcomes or trends from competitors; future topline data timing or results; our ability to prevent and/or mitigate cyber-attacks; our ability to protect our intellectual property rights; the uncertainties inherent in clinical testing; uncertainties concerning analyses or assessments outside of a controlled clinical trial; and changes in laws and regulations applicable to our business and our ability to comply with such laws and regulations. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal’s submissions filed with the U.S. Securities and Exchange Commission (SEC) for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. Madrigal specifically discusses these risks and uncertainties in greater detail in the sections appearing in Part I, Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2025, and as updated from time to time by Madrigal’s other filings with the SEC.

Madrigal may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Madrigal’s website in addition to following its press releases, filings with the SEC, public conference calls, and webcasts.

Madrigal Pharmaceuticals, Rezdiffra^® and associated logos are trademarks of Madrigal Pharmaceuticals, Inc.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Krysta Pellegrino, media@madrigalpharma.com

New resource hub builds on Collegium’s growing ADHD portfolio and commitment to supporting people and families beyond the clinical setting

STOUGHTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, launched Start Talking ADHD, an online resource hub offering practical guides to people living with attention-deficit/hyperactivity disorder (ADHD), and the families who support them. The guides are designed to help patients and caregivers prepare for conversations with healthcare providers, school administrators, and the people in their support networks.

ADHD is a neurodevelopmental disorder characterized by patterns of inattention, hyperactivity and impulsivity, or a combination of both, at a level that interferes with functioning or development.¹ An estimated 7 million children and 15.5 million adults in the U.S. have ADHD.^2,3 For many people living with ADHD, the moments that matter most are also the hardest to describe like the scramble before the school bus, the homework hour, the tasks that pile up after the workday ends. Helping people identify and communicate what happens during these everyday moments can support more informed conversations about their needs.

“The clearest picture of ADHD comes from understanding how it shows up throughout the day,” said Ingrid McPhilliamy, General Manager, ADHD, Collegium Pharmaceutical, Inc. “The support that makes the biggest difference often comes from the people who see the day-to-day and building that circle takes intention. This input can be an important part of painting a more specific picture that a family can share with their care team, ultimately leading to a more productive conversation.”

ADHD Resources for Healthcare, School and Everyday Support Conversations

Start Talking ADHD includes three downloadable guides, each designed support different conversations:

• ADHD Doctor Discussion Guide. A fill-in worksheet that walks through a typical day, across mornings, daytime, afternoons, evenings and sleep, so a parent, caregiver or adult with ADHD can arrive at a healthcare appointment with concrete examples of daily experiences.
• 504 Plan/Individualized Education Program (IEP) Educational Guide. A side-by-side explanation of the 504 Plans and Individualized Education Programs (IEPs), two main pathways for school support, plus a seven-step overview of the evaluation process, a preparation checklist, a glossary of key terms, and links to resources including Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) and the U.S. Department of Education.
• Building Your Community of Support Guide. A worksheet for mapping a personal ADHD support network across home, school and the healthcare team, plus a directory of national advocacy, caregiver, school-support and mental-wellness organizations.

These guides are educational and do not diagnose ADHD or recommend any specific treatment.

Expanding Collegium’s Commitment to ADHD

Over the last year, Collegium has expanded its presence and investment in ADHD, including adding a second medicine to its portfolio in May 2026 and extending the company’s long-term commitment.

“Leadership in ADHD starts with listening to the people who live with it and acting on what we hear,” said Vikram Karnani, President and Chief Executive Officer, Collegium Pharmaceutical, Inc. “Medicine is an important part of our work, but support extends beyond a prescription. With Start Talking ADHD, we’re providing straightforward information to help people living with ADHD and those who support them have more informed conversations with doctors, schools and each other.”

Collegium’s commitment extends into the community. In February 2026, Collegium became an Official Partner of Boston Legacy Football Club, the National Women’s Soccer League’s 15th club, sponsoring the Collegium Sensory Room at the club’s home matches. This room, designed with input from CHADD, offers a quieter space for fans who need a break from the noise, crowds and visual stimulation of a matchday. Together, Boston Legacy FC and Collegium are helping to create access to youth and family experiences across the Boston area, including local adaptive soccer clinics and player engagements.

About Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions.

With a portfolio of differentiated ADHD medications and an established leadership position in responsible pain management, Collegium leads with the scientific rigor and commercial expertise to deliver treatment options around how people live their lives. For more information, please visit collegiumpharma.com or find us on LinkedIn.

Investor Contact:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com

Media Contact:
Jessica Cotrone
Senior Vice President, Corporate Communications & Corporate Affairs
communications@collegiumpharma.com

REFERENCES

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). Washington, DC: American Psychiatric Association Publishing; 2022.
2. Centers for Disease Control and Prevention. Data on ADHD in Children. https://www.cdc.gov/adhd/data/index.html. Estimate based on 2024 National Survey of Children’s Health data. Accessed August 2026.
3. Staley BS, Robinson LR, Claussen AH, et al. Attention-Deficit/Hyperactivity Disorder Diagnosis, Treatment, and Telehealth Use in Adults — National Center for Health Statistics Rapid Surveys System, United States, October–November 2023. MMWR Morb Mortal Wkly Rep. 2024;73(40):890–895.

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) — Ormat Technologies, Inc. (NYSE: ORA) (the “Company” or “Ormat”), a leading geothermal and renewable energy company, today announced that it plans to publish its third quarter financial results in a press release that will be issued on Wednesday, November 4, 2026, after the market closes. In conjunction with this report, the Company has scheduled a conference call to discuss the results at 10:00 a.m. ET on Thursday, November 5, 2026.

Participants within the United States and Canada, please dial 1-833-461-5787, approximately 15 minutes prior to the scheduled start of the call. If you are calling from outside the United States or Canada, please dial +1-585-542-9983. The access code for the call is 244015737. Please request the “Ormat Technologies, Inc. call” when prompted by the conference call operator. The conference call will also be accompanied by a live webcast, accessed on the Investor Relations section of the Company’s website.

A replay will be available one hour after the end of the conference call. To access the replay within the United States and Canada, please dial 1-833-309-1852. From outside of the United States and Canada, please dial +1-929-828-5978. Please use the replay access code 244015737. The webcast will also be archived on the Investor Relations section of the Company’s website.

ABOUT ORMAT TECHNOLOGIES

With over six decades of experience, Ormat Technologies, Inc. is a leading geothermal company, and the only vertically integrated company engaged in geothermal and recovered energy generation (“REG”), with robust plans to accelerate long-term growth in the energy storage market and to establish a leading position in the U.S. energy storage market. The Company owns, operates, designs, manufactures and sells geothermal and REG power plants primarily based on the Ormat Energy Converter – a power generation unit that converts low-, medium- and high-temperature heat into electricity. The Company has engineered, manufactured and constructed power plants, which it currently owns or has installed for utilities and developers worldwide, totaling approximately 3,600MW of gross capacity. Ormat leveraged its core capabilities in the geothermal and REG industries and its global presence to expand the Company’s activity into energy storage services, solar Photovoltaic (PV) and energy storage plus Solar PV. Ormat’s current total generating portfolio is 1,850MW with a 1,355MW geothermal and solar generation portfolio that is spread globally in the U.S., Kenya, Guatemala, Indonesia, Honduras, and Guadeloupe, and a 495MW energy storage portfolio that is located in the U.S.

Ormat is the only single-solution company with tangible and proven end-to-end capabilities to commercialize, scale, and operate Enhanced Geothermal Systems. As electricity demand accelerates, driven by AI data centers, electric vehicles, industrial reshoring, and the electrification of heating and cooling, Ormat’s geothermal and EGS capabilities position the Company to help meet this growing demand and lead technological advancement in the market. The Company’s industry-leading business model and strong reputation are built on long-standing expertise, operational excellence, high-performance teams, and delivering reliable long-term energy generation.

Ormat Technologies Contact: Smadar Lavi VP, Head of IR and ESG Planning & Reporting 775-356-9029 (ext. 65726) slavi@ormat.com

Investor Relations Agency Contact: Joseph Caminiti or Josh Carroll Alpha IR Group 312-445-2870 ORA@alpha-ir.com

Company exercises options for two additional, attractively priced mid-size newbuildings delivering 4Q29

ATHENS, Greece, Oct. 06, 2026 (GLOBE NEWSWIRE) — Global Ship Lease, Inc. (NYSE:GSL) (the “Company” or “Global Ship Lease”), a containership owner and lessor, today announced that, subject to certain conditions precedent being met, the Company has exercised options to build two additional mid-size, ultra-high-reefer, wide-beam, latest-generation containerships (the “Additional Newbuilds”) for an aggregate contract price of approximately $163 million. These highly flexible ships have been designed and specified to ensure a superior fit for existing and anticipated future market needs. The Additional Newbuilds are scheduled to be delivered in the fourth quarter of 2029, and the Company is in discussions with prospective charterers regarding their employment upon delivery. With these Additional Newbuilds, the Company’s newbuilding orderbook is 17 ships.

George Youroukos, Executive Chairman of Global Ship Lease, commented: “We are strong believers in the value proposition of high specification, highly flexible, mid-sized containerships and expect them to play a crucial role for our industry for many years to come. By exercising these additional newbuild options, we are very pleased to be growing our exposure to this increasingly valuable vessel class on attractive terms agreed earlier this year and at prices no longer available in the market for comparably specified ships with 2029 deliveries.”

About Global Ship Lease 

Global Ship Lease is a leading independent owner of containerships with a diversified fleet of mid-sized and smaller containerships. Incorporated in the Marshall Islands, Global Ship Lease commenced operations in December 2007 with a business of owning and chartering out containerships under fixed-rate charters to top tier container liner companies. It was listed on the New York Stock Exchange in August 2008.

Our operating fleet of 71 containerships as of June 30, 2026, had an average age weighted by TEU capacity of 18.4 years. 41 ships are wide-beam Post-Panamax. As of June 30, 2026, our fleet also included 15 newbuilding containerships under construction with scheduled deliveries between the fourth quarter of 2028 and the first quarter of 2030 (the “Initial Newbuilds”).

As of June 30, 2026, the average remaining term of the Company’s charters, to the mid-point of redelivery, including options under the Company’s control and other than if a redelivery notice has been received, including the Initial Newbuilds, was 3.3 years on a TEU-weighted basis. Contracted revenue on the same basis was $3.2 billion. Contracted revenue was $4.1 billion, including options under charterers’ control and with latest redelivery date, representing a weighted average remaining term of 4.4 years.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements provide the Company’s current expectations or forecasts of future events. Forward-looking statements include statements about the Company’s expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “will” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. These forward-looking statements are based on assumptions that may be incorrect, and the Company cannot assure you that the events or expectations included in these forward-looking statements will come to pass. Actual results could differ materially from those expressed or implied by the forward-looking statements as a result of various factors, including the factors described in “Risk Factors” in the Company’s Annual Report on Form 20-F and the factors and risks the Company describes in subsequent reports filed from time to time with the U.S. Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.

Investor and Media Contact: 
IGB Group 
Bryan Degnan 
646-673-9701 
or 
Leon Berman 
212-477-8438 

FORT WAYNE, Ind., Oct. 06, 2026 (GLOBE NEWSWIRE) — Fort Wayne Medical Oncology and Hematology (FWMOH), a partner practice of American Oncology Network (AON), has launched a new radiation oncology division, Fort Wayne Radiation Oncology. The Fort Wayne Radiation Oncology clinic, located at 10307 Dupont Circle Drive West, Suite B, Fort Wayne, IN 46825, is now open Monday through Friday from 8 a.m. to 4:30 p.m. Prospective patients can call 260-818-7001 with questions or to schedule an appointment.

Fort Wayne Radiation Oncology is led by Board-certified radiation oncologists Mark Ranck, MD; Nathan Comsia, MD; and Zhigang Yuan, MD, PhD; of Radiation Oncology Associates.

“We are excited to be part of Fort Wayne Radiation Oncology in collaboration with Fort Wayne Medical Oncology and Hematology,” said Dr. Ranck. “Together, we share a commitment to ensuring community oncology patients have access to comprehensive cancer care and advanced imaging and treatment technologies. Our patients can expect the same level of compassionate care they receive at Fort Wayne Medical Oncology and Hematology.”

The state-of-the-art clinic offers comprehensive radiation oncology services, access to clinical trials and cutting-edge treatments, including the latest advances in linear accelerator technology.

“We are thrilled to open this new division of Fort Wayne Medical Oncology and Hematology,” said Dr. Praveen Kollipara, Board-certified medical oncologist and hematologist at Fort Wayne Medical Oncology and Hematology. “Offering radiation oncology services expands our patients’ access to exceptional cancer care and further enhances the high-quality care we provide to our community.”

For more information about Fort Wayne Radiation Oncology, visit fortwayneradiationoncology.com. For more information about Fort Wayne Medical Oncology and Hematology, visit fwmoh.com. To learn more about American Oncology Network, visit AONcology.com.

About Fort Wayne Medical Oncology and Hematology

Fort Wayne Medical Oncology and Hematology (FWMOH) provides state-of-the-art cancer and blood disorder treatments through a team of dedicated healthcare providers serving northeastern Indiana. Since 1977, FWMOH has cared for thousands of patients, treating more than 40 types of cancer – from bladder to bone, pancreatic to prostate – as well as blood disorders such as hemophilia, sickle cell anemia, and idiopathic thrombocytopenic purpura (ITP).

FWMOH’s experience physicians, nurse practitioners, nurses, and clinical support staff work collaboratively to deliver the high-quality oncologic and hematologic care informed by cutting-edge research and decades of experience. The team emphasizes compassionate, patient-centered care that respects the needs of the whole person.

The following Board-certified physicians are accepting appointments at FWMOH: Farrukh M. Adhami, MD; Sunil Babu, MD; Matthew L. Carr, MD; Shalini Chitneni, MD; Michael Epstein, MD; Gary G. Gize, MD; Ryan Gonzales, MD; Praveen Kollipara, MD; Yasolatha Nalamolu, MD; Sreenivasa R. Nattam, MD; Dolly Rosa Quispe, MD; Steven N. Rhinehart, MD; Ahad Sadiq, MD; Naga Vutukuri, MD; Richard Zhang, MD; and David M. Zimmerman, MD. FWMOH’s gynecologic oncologists include Dr. Iwona Podzielinski and Dr. Scott Goodrich.

Learn more at fwmoh.com.

About American Oncology Network

American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 350 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com or follow us on LinkedIn, Facebook, X (formerly Twitter) and YouTube.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6d0ed74a-81de-4508-b402-3d37efcc143a

CONTACT: Media Contact:
Karen Riley Sawyer
American Oncology Network
Karen.Sawyer@AONcology.com

Project establishes a blueprint for future deployments across additional communities managed by the Forza Esmeralda Group

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) — Veea Inc., a leader in edge computing, intelligent connectivity, cybersecurity, and AI-powered edge applications, today announced the successful signing of a one-year agreement with La Estadia Community of 220 exclusive residential properties to deploy Veea’s SecureConnect™ platform and Veea Vision™ AI video analytics solution across the community’s network infrastructure.

The project will deliver a secure, managed digital infrastructure that combines enterprise-grade connectivity, cybersecurity, and AI-powered video inferencing at the edge to enhance operational efficiency, resident safety, and community management.

Under the agreement, Veea will deploy its SecureConnect platform to provide secure networking, centralized management, and advanced cybersecurity capabilities throughout the community. In addition, Veea Vision will enable intelligent video analytics through edge-based AI processing, allowing cameras to generate real-time insights while minimizing bandwidth consumption and reducing reliance on cloud-based processing.

“This deployment demonstrates how communities can modernize their infrastructure while improving security, operational visibility, and residents’ quality of life and daily experience in a residential community,” said Helder Antunes, Chief Revenue Officer of Veea. “By combining secure connectivity with AI-powered video analytics and automated personalized notifications for each residential unit, we are enabling a real-time aware community and more secure environments while reducing complexity and ongoing operational costs.”

The deployment represents the first phase of a broader strategic opportunity between Veea and Forza Esmeralda Group. The parties are currently evaluating expansion opportunities across seven additional communities managed by the group, as well as multi-year managed services agreements that would provide ongoing deployment, monitoring, maintenance, cybersecurity, and lifecycle management services.

“We didn’t want more cameras. We wanted smarter ones,” said Hector Silva, President of La Estadia Community. “With Veea, our security team gets real-time awareness instead of hours of footage to review, and our residents get a connected community they can count on. We wanted one partner who could deliver all of it on a single platform and grow with us, and Veea was that partner.”

The project highlights the growing demand for intelligent edge infrastructure within residential communities, mixed-use developments, smart buildings, and distributed properties seeking to improve security, connectivity, and operational efficiency without the complexity associated with traditional multi-vendor solutions.

Veea’s integrated platform enables organizations to converge networking, cybersecurity, IoT, edge computing, and AI applications into a single architecture managed through a centralized cloud platform.

If the initial deployment achieves its targeted objectives, the parties expect to explore expansion opportunities that could significantly increase the scope of the relationship over the coming years.

About Veea

Veea Inc. (NASDAQ: VEEA) is a global leader in edge solutions and infrastructure. Founded in 2014 and headquartered in New York City, Veea enables enterprises, service providers and public sector organizations to deploy AI-powered applications at the edge. The VeeaONE platform integrates connectivity, computing, cybersecurity and storage into a unified hyperconverged network solution, from edge to cloud. Veea holds more than 123 patents across related technology domains and has been recognized by Gartner for its innovations in edge computing. www.veea.com

Media contact

Thomas Latiolais · Veea Inc. · thomas.latiolais@veea.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements typically include projections of future revenues, earnings, strategies, and operational growth. These statements are based on current beliefs, assumptions and expectations and involve known and unknown risks and uncertainties that could cause actual results to differ materially from current projections due to factors including, but not limited to, market conditions, economic shifts, and operational challenges. Operational factors that could cause results to differ include Veea’s ability to maintain adequate financial resources, execute its growth strategy, achieve market acceptance, and compete effectively. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “will” and similar expressions. Forward-looking statements speak only as of the date made. Veea disclaims any obligation to update them publicly.

EINDHOVEN, The Netherlands, Oct. 06, 2026 (GLOBE NEWSWIRE) — NXP Semiconductors N.V. (NASDAQ: NXPI) today announced it will release financial results for the third quarter 2026 after the close of normal trading on the NASDAQ Global Select Market on Tuesday, October 27, 2026. The company will host a conference call with the financial community at 4:30 p.m. U.S. Eastern Daylight Time (EDT) the same day.

Earnings Conference Call Details 
Interested parties may pre-register for the webcast or obtain a user-specific access code to join the live conference call.

A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call.

About NXP Semiconductors 

NXP Semiconductors N.V. (NASDAQ: NXPI) is the trusted partner for innovative solutions in the automotive, industrial & IoT, mobile, and communications infrastructure markets. NXP’s “Brighter Together” approach combines leading-edge technology with pioneering people to develop system solutions that make the connected world better, safer, and more secure. The company has operations in more than 30 countries and posted revenue of $12.27 billion in 2025. Find out more at www.nxp.com.

For further information, please contact: 

Investor:	Media:
Mike Lucarelli	Paige Iven
mike.lucarelli@nxp.com	paige.iven@nxp.com
+1 617 943 6892	+1 817 975 0602

NXP-CORP

New SailPoint Human Fabric capabilities and SailPoint IdentityIQ 9.0 release deliver security and governance built for enterprise scale, ensuring no customer is left behind in their security evolution

AUSTIN, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) — Today at its annual flagship conference, Navigate, SailPoint, Inc. (Nasdaq: SAIL), a leader in enterprise identity security, announced a significant modernization across its entire identity platform. The company unveiled new enterprise-scale capabilities for SailPoint Human Fabric and the release of IdentityIQ 9.0, a major update to its on-premises solution. These updates demonstrate a unified commitment to modernizing identity security for every customer, whether in the cloud, on-premises, or in a hybrid environment.

The announcements address a challenge facing the industry as a whole: most identity governance infrastructure can’t keep pace with how enterprises operate today. SailPoint is closing that gap with substantive updates that re-platform core services for scale and strengthen governance, not simple UI refreshes.

Chandra Gnanasambandam, EVP of Product and Chief Technology Officer at SailPoint, said:
“Most vendors ask their customers to choose between a growth story or a stewardship story, but the reality of the modern enterprise is not that simple. Today, we are delivering on both fronts. We are advancing the frontier of cloud identity security with Human Fabric while also demonstrating our commitment to the customers who rely on IdentityIQ for identity security. This is one modernization effort on two fronts, ensuring every customer has a path forward without compromise.”

Governance built for enterprise scale: The SailPoint Human Fabric
SailPoint announced three new major updates for Human Fabric, its cloud-native identity security product, designed to operate at enterprise scale:

• Access certifications enhancements: A completely re-platformed certification engine built to handle enterprise-scale access reviews without record limits or data delays. The new engine removes the need for administrators to manually split large campaigns and includes a faster, more intuitive reviewer interface and cryptographic, GxP-compliant sign-off for regulated industries.
• Proactive Separation of Duties (SoD): Moving beyond after-the-fact alerting, SailPoint’s enhanced SoD engine provides real-time evaluation that proactively blocks toxic access combinations at the moment of request. It uniquely flags conflicts created by other pending requests still in-flight, preventing violations before they occur.
• Conversational Access Requests: A new AI-powered agent allows users to make access requests in natural language directly from their chat tools. With support for custom forms, employees can provide necessary business justifications and compliance details seamlessly within the chat flow.

No customer left behind: IdentityIQ 9.0
For customers with extensive data residency requirements, strict regulatory constraints, or deeply customized programs, SailPoint is delivering IdentityIQ 9.0. The release provides a parallel modernization path for hybrid and on-premises deployments, centered on three pillars: a stronger governance, including granular, time-based access for roles and entitlements, and a rebuilt technical foundation running on modern application servers, with a refreshed user experience that streamlines access reviews and application definition.

Critically, SailPoint is also offering an automated upgrade tool with the release. This utility scans a customer’s environment and automates much of the manual work required to update, addressing the primary risk that stalls on-premises upgrades and proving that customers can confidently evolve their existing deployments.

Learn more about all the new products announced today at Navigate here.

About SailPoint
SailPoint (Nasdaq: SAIL) is defining the new era of adaptive identity security. In a world where non-human identities now significantly outnumber humans, our AI-powered platform unifies identity, security, and data intelligence to protect today’s enterprise from advanced identity-based threats. We deliver the identity solution that spans both the breadth of identities and the depth of context needed to drive real-time access with confidence. Built on principles like zero-standing privilege and contextualized risk, our SailPoint platform transforms identity from a point of vulnerability into a powerful security advantage. Trusted by many of the world’s leading organizations, SailPoint secures the enterprise with intelligent, autonomous identity security.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to SailPoint’s expectations regarding announcements made at Navigate. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “expects,” “plans,” “anticipates,” “could,” “would,” “plan to,” “intend to,” “believe,” or “goal” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These forward-looking statements are not guarantees of future performance, but are based on management’s current expectations, assumptions and beliefs concerning future developments and their potential effect on us, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. Our expectations expressed or implied in these forward-looking statements may not turn out to be correct. The development, release, and timing of any features or functionality described for SailPoint’s products that are not currently available remain at SailPoint’s sole discretion on a when, and if available, basis, may not be delivered at all and should not be relied on in making a purchasing decision, and could be materially different from our expectations because of various risks.

Important factors, some of which are beyond our control, that could cause actual results to differ materially from our historical results or those expressed or implied by these forward-looking statements include the following: our ability to deepen our relationships with existing customers; the growth in the market for identity security solutions; our ability to maintain successful relationships with each of our partners; our ability to compete successfully against current and future competitors; the increasing complexity of our operations; our ability to maintain and enhance our brand or reputation as an industry leader and innovator; unfavorable conditions in our industry or the global economy; our ability to successfully introduce, use, and integrate artificial intelligence (AI) with our solutions; breaches in our security, cyber attacks, or other cyber risks; interruptions, outages, or other disruptions affecting the delivery of our SaaS solution or any of the third-party cloud-based systems that we use in our operations; our ability to adapt and respond to rapidly changing technology, industry standards, regulations, or customer needs, requirements, or preferences; real or perceived errors, failures, or disruptions in our platform or solutions; and the ability of our platform and solutions to effectively interoperate with our customers’ existing or future IT infrastructures.

More information on these risks and other potential factors that could affect our financial results is included in our reports and other documents filed with the Securities and Exchange Commission including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in our most recently filed Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date as of which such statement is made, and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether because of new information, future events, or otherwise.

The development, release, and timing of any features, functionality, capabilities, or services described for SailPoint’s products that are not currently available remain at SailPoint’s sole discretion on a when, and if, available basis and may not be delivered at all and must not be relied on in making a purchasing or investing decision.

Media relations for SailPoint
Shannon Paulk
Sr. Manager, Corporate Communications
303-748-2275
shannon.paulk@sailpoint.com

Date: Thursday, November 5, 2026
Time: 10:00am (Eastern Time)

BROOKFIELD, NEWS, Oct. 06, 2026 (GLOBE NEWSWIRE) — Brookfield Business Corporation will host its Third Quarter 2026 Conference Call & Webcast on Thursday, November 5, 2026 at 10:00 a.m. (ET) to discuss results and current business initiatives.

Results will be released on Thursday, November 5, 2026 prior to 8:00 a.m. (ET) and will be available following the release on our website at https://bbuc.brookfield.com.

Participants can join by conference call or webcast:

Conference Call

• Please pre-register: BBUC2026Q3ConferenceCall
• Upon registering, you will be emailed a dial-in number and unique PIN. This process will bypass the operator and avoid the queue.

Webcast

• Please join and register by webcast: BBUC2026Q3Webcast
• A replay of the webcast will be available on our website.

Brookfield Business Corporation (NYSE, TSX: BBUC) is a global owner and operator of vital industrial and business services operations. Our objective is to acquire market-leading businesses for value, execute our operational improvement plans to increase cash flows and recycle capital to compound long-term growth. For more information, please visit https://bbuc.brookfield.com.

Brookfield Business Corporation is the flagship vehicle of Brookfield Asset Management’s Private Equity Group. Brookfield Asset Management is a leading global alternative asset manager with over $1 trillion of assets under management.  

For more information, please contact:

Media: Simon Maine Tel: +44 7398 909 278 Email: simon.maine@brookfield.com

Investors: Alan Fleming Tel: +1 (416) 645 2736 Email: alan.fleming@brookfield.com